Elicio Therapeutics


Elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer.

Industries

Employees

11-50

Links


Org chart

Collapse
Peter C. DeMuth
Chief Scientific Officer
Christopher Haqq
EVP, Head of R&D & CMO
Michael Divecchia
SVP, Operations & Human Resources
Alaina Ownbey
Vp, Finance
Megan Filoon
General Counsel, Secretary & Compliance Officer

Board & advisors